Canada markets closed

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.10500.0000 (0.00%)
At close: 01:53PM EDT
Full screen
Previous Close0.1050
Open0.1000
Bid0.1000 x N/A
Ask0.1050 x N/A
Day's Range0.1000 - 0.1050
52 Week Range0.0100 - 0.1900
Volume128,500
Avg. Volume53,714
Market Cap4.178M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Marvel Biosciences Announces Private Placement

    Calgary, Alberta--(Newsfile Corp. - May 16, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $1,000,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (a ...

  • Newsfile

    Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

    Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology. Tau phosphorylation is a process where phosphates attach to a Tau protein in the brain. When Tau proteins become overly phosph

  • Newsfile

    Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

    Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBrain Institute in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore social interaction behaviors to normal levels in autism model mice, with ..